Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

Probert, C.S.J.; Hearing, S.D.; Schreiber, S.; Kühbacher, T.; Ghosh, S.; Arnott, I.D.R.; Forbes, A.
July 2003
Gut;Jul2003, Vol. 52 Issue 7, p998
Academic Journal
Background: Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in ulcerative colitis. Methods: We conducted a randomised placebo controlled trial of infliximab (5 mg/kg) in the treatment of glucocorticoid resistant ulcerative colitis. Infusions were given at weeks 0 and 2. Disease activity and quality of life were recorded over eight weeks of follow up. Remission was defined as an ulcerative colitis symptom score (UCSS) of ≤ 2 and/or Baron score of 0 at week 6. Patients not in remission were offered open label infliximab 10 mg/kg and reviewed two weeks later. Results: After two weeks, there was no statistically significant difference between the infliximab and placebo groups in the proportion of patients with a Baron score of 0 (13% (3/23) v 5% (1/19) (95% confidence interval (CI) -9% to 24%); p = 0.74). After six weeks, remission (UCSS ≤ 2) rates were 39% (9/23) versus 30% (6/20) (95% CI -19 to 34%; p = 0.76). The median improvement in UCSS was 3 for the infliximab group and 2.5 for the placebo group (p = 0.82, Mann-Whitney U test). A Baron score of 0 was likely in either group (26% (6/23) v 30% (6/20) (95% CI -30% to 23%); p = 0.96). Improvement in the IBDQ and EuroQol was not significantly different between the groups (p = 0.22 and 0.3, respectively, Mann-Whitney U test). Twenty eligible patients were given open labelled infusions. Remission was achieved in 3/11 (27%) patients initially treated with infliximab and in 1/9 (11%) patients treated with placebo. Conclusion: These data do not support the use of infliximab in the management of moderately active glucocorticoid resistant ulcerative colitis.


Related Articles

  • Golimumab for the treatment of ulcerative colitis. Löwenberg, Mark; de Boer, Nanne KH; Hoentjen, Frank // Clinical & Experimental Gastroenterology;2014, Vol. 7, p53 

    The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile....

  • Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. Papa, Alfredo; Mocci, Giammarco; Bonizzi, Michele; Felice, Carla; Andrisani, Gianluca; De Vitis, Italo; Guidi, Luisa; Gasbarrini, Antonio // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1575 

    With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we...

  • Current and Emerging Biologics for Ulcerative Colitis. Sung Chul Park; Yoon Tae Jeen // Gut & Liver;Jan2015, Vol. 9 Issue 1, p18 

    Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being investigated for treating ulcerative colitis....

  • Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Fausel, Rebecca; Afzali, Anita // Therapeutics & Clinical Risk Management;2015, Vol. 11, p63 

    Ulcerative colitis can cause debilitating symptoms and complications such as colonic strictures, colonic dysplasia, colorectal cancer, and toxic megacolon or perforation. Goals of treatment in ulcerative colitis include resolution of gastrointestinal symptoms, healing of colonic mucosa, and...

  • Infliximab therapy in pediatric Crohn's disease: a review. Parashette, Kalyan Ray; Makam, Raghavendra Charan; Cuffari, Carmen // Clinical & Experimental Gastroenterology;2010, Vol. 3, p57 

    Anti-tumor necrosis factor alpha (TNF-α) therapy has re-defined our treatment paradigms in managing patients with Crohn's disease (CD) and ulcerative colitis. Although the ACCENT studies showed proven efficacy in the induction and maintenance of disease remission in adult patients with...

  • Gene Expression Profiling and Response Signatures Associated With Differential Responses to Infliximab Treatment in Ulcerative Colitis. Toedter, Gary; Li, Katherine; Marano, Colleen; Ma, Keying; Sague, Sarah; Huang, C Chris; Song, Xiao-Yu; Rutgeerts, Paul; Baribaud, Frédéric // American Journal of Gastroenterology;Jul2011, Vol. 106 Issue 7, p1272 

    OBJECTIVES:Infliximab has been shown to induce clinical response and remission in ulcerative colitis (UC). To characterize the biological response of patients to infliximab, we analyzed the mRNA expression patterns of mucosal colonic biopsies taken from UC patients enrolled in the Active...

  • The incidence and management of infusion reactions to infliximab: a large center experience. Cheifetz, Adam; Smedley, Michelle; Martin, Sara; Reiter, Monica; Leone, Grace; Mayer, Lloyd; Plevy, Scott // American Journal of Gastroenterology;Jun2003, Vol. 98 Issue 6, p1315 

    : ObjectiveTo assess the incidence and management of infusion reactions to infliximab, a chimeric monoclonal antibody that targets human tumor necrosis factor-α, in patients with Crohn’s disease treated at a large infusion center.: MethodsA total of 165 consecutive patients who...

  • Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review. Filippi, Jérôme; Allen, Patrick B.; Hébuterne, Xavier; Peyrin-Biroulet, Laurent // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1440 

    Infliximab has demonstrated its efficacy in moderate to severe ulcerative colitis. The Active Ulcerative Colitis Trial (ACT) -1 and 2 have demonstrated the beneficial impact of infliximab on the short-term colectomy rate. However, data evaluating this outcome beyond one year remains scarce. To...

  • Which Biological Agents Are Most Appropriate for Ulcerative Colitis? Nielsen, Ole Haagen; Ainsworth, Mark Andrew // Annals of Internal Medicine;5/20/2014, Vol. 160 Issue 10, Following p733 

    The article reflects on the biological agents which are appropriate for the treatment of ulcerative colitis. Topics discussed include use of 5-aminosalicylic acids, glucocorticoids, and immunomodulators in the traditional treatment of the disease, use of drugs containing infliximab, vedolizumab,...


Read the Article


Sign out of this library

Other Topics